03-15-2010: Evotec AG announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

Evotec will use its expertise and technologies in assay development, high throughput screening (HTS) and surface plasmon resonance (SPR) screening for the identification and validation of novel hits. In order to maximise the probability of finding high quality medicinal chemistry starting points, Evotec will screen its Lead Discovery Library, a small molecule collection designed for diversity, novelty and quality.

No financial details are disclosed.

Contact / Request information

Request further information free of charge:

Facts, background information, dossiers
  • medicinal chemistry
  • lead discovery
More about Evotec
Most read news
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE